Article
Clinical distinctions of anti-topoisomerase positive limited cutaneous systemic sclerosis in early disease: results from the early Systemic sclerOsis Longitudinal Assessment Registry from Turkey.
Clinical and experimental rheumatology - 1 Aug 2026
Yayla Müçteba Enes, Okyar Burak, Ersözlü Emine Duygu, Özgür Duygu Sevinç, Bes Cemal, Çefle Ayşe, Firlatan Yazgan Büşra, Kimyon Gezmiş, Turgay Tahsin Murat, Baltaci Mehmet Akif, Avanoglu Guler Aslihan, Vasi Ibrahim, Erden Abdulsamet, Bilici Reyhan, Sulu Bercemhan, Varkal Gizem, Arslan Didem, Uğurlu Zübeyde, Doğru Atalay, Avcu Ayşegül, Alibaz-Oner Fatma, Yurttaş Berna, Güven Serdar Can, Erten Şükran, Küçükşahin Orhan, Kahraman Denizhan Tuğba, Şenel Soner, Yamancan Gülsah, Karatas Ahmet, Genç Esra, Tezcan Mehmet Engin, Dogan Agbuga Özlem, Amikishiyev Shirkhan, Babayigit Arif, Şahin Ali, Yildirim Reşit, Kaşifoğlu Timuçin, Aslan Bengisu, Öğüt Tahir Saygın, Zengin Orhan, Albayrak Fatih, Er Gülbezer Elif, Yazısız Veli, Birlik Merih, Hatemi Gülen, Yalçınkaya Yasemin, Inanç Murat, Koca Süleyman Serdar, Temiz Karadağ Duygu, Erdogan Mustafa, Sarı Alper, Akdogan Ali
Abstract excerpt
OBJECTIVES: Anti-topoisomerase I antibody (ATA) is typically associated with diffuse cutaneous systemic sclerosis (dcSSc). However, subset of limited cutaneous SSc (lcSSc) patients also present with ATA positivity. Emerging data suggest that ATA-positive lcSSc may represent a distinct or intermediate clinical phenotype. This study aimed to compare the demographic, clinical, and treatment features of early...
Topics
- Humans
- Female
- Registries
- Male